Why the study?
Do blood levels of thromboxane and 6-keto-PGF1α change during ramipril therapy to serve as potential biomarkers for ACE inhibitor-induced angioedema risk?
Do blood levels of thromboxane and 6-keto-PGF1α change during ramipril therapy to serve as potential biomarkers for ACE inhibitor-induced angioedema risk?
Determination of 6-keto-PGF1α is feasible and may serve as a valuable blood biomarker for assessing the risk of developing ACE inhibitor-induced angioedema.
Hypothesis-generating for ACEi-AE biomarkers; prospective validation needed before any clinical application.
BACKGROUND: Angiotensin-converting enzyme inhibitor-induced angioedema (ACEi-AE) is the most frequent drug-induced angioedema. The aim of this study was to evaluate potential biomarkers for the detection of the risk to develop an ACEi-AE. METHODS: Adult patients who started antihypertensive treatment with ramipril were included and followed up for 4-6 weeks. At baseline, 3 days, and 4-6 weeks after onset of therapy, blood samples were obtained. RESULTS: Twenty-four patients could be enrolled. The thromboxane values were very heterogeneous, and none of the group differences observed was statistically significant. The values obtained for 6-keto-prostaglandin F1α (6-keto-PGF1α) showed a statistically significant increase with 10 mg/day doses under ramipril therapy. CONCLUSIONS: In this small patient population, it could be shown that determination of 6-keto-PGF1α is feasible. It may prove to be a valuable blood marker for assessing the risk of developing ACEi-AE.
No takes yet. Share an insight, caveat, or question.
Baş et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: